Introduction
Among seven known classes of receptors for serotonin (5-hydroxytryptamine: 5-HT), the 5-HT 3 receptor is unique as being a ligand-gated ion channel. 1 It is structurally similar to other neurotransmitter-dependent ion channels which also includes the nicotinic acetylcholine channel/receptor. 2, 3 Unlike other 5-HT receptors, 5-HT 3 receptor causes an early depolarization effect in postsynaptic membranes by directly conducting Na + , K + and Ca 2+ ions. 1, 4 As shown in animal brains, serotonergic brainstem projections have excitatory effects on target neurons expressing 5-HT 3 receptors. 5 These targets are generally a subset of inhibitory interneurons in cerebral neocortex 6 and hippocampus, 5,7-9 resulting in an overall inhibitory effect despite the excitatory nature of the receptor. Besides the conventional synapse formation, serotonergic axons show a paracrine release of 5-HT through varicose axonal fibers. 10 According to accumulating evidence, epileptic seizures can be induced or amplified by experimental manipulations that attenuate serotonergic neurotransmission. 11 In contrast, augmentation of serotonin activity in the brain, either by dietary manipulation, 12 administration of 5-hydroxytryptophan 13 or selective serotonin reuptake inhibitors (SSRIs), 14, 15 or via dorsal raphe nucleus stimulation 16 has been reported to be anticonvulsant. In a recent review by Lö scher, 17 the apparent biphasic effect of antidepressants on seizure threshold was documented: low but clinically relevant doses of antidepressants appear to exert an anticonvulsant effect in a variety of animal seizure models (e.g. the i.v. PTZ seizure threshold) in mice and rats via an increase in noradrenaline or 5-HT synaptic levels, while proconvulsant activity may be seen at higher or supratherapeutic doses of PTZ or other proconvulsant and other models. Furthermore, increase in extracellular 5-HT concentration has been suggested to be an underlying mechanism for the action of some well-known antiepileptic drugs.
considered as both neurotransmitter and neuromodulator, 21, 22 acting mainly through increasing levels of cyclic GMP (cGMP). 23, 24 Neuronal NOS (nNOS) activity is well known to be regulated by membrane channel/receptors, including glutamate N-methyl-Daspartate (NMDA) receptor and gamma amino butyric acid (GABA) A receptor, as well as intracellular signaling mediators such as Ca 2+ . 25, 26 Since 5-HT 3 receptor activation could increase the calcium influx directly through its ion channel component activation or indirectly by affecting other calcium regulating mechanisms, 27 one may hypothesize an NO-mediated intracellular signaling for 5-HT 3 receptor activation. To date, no one has reported such interaction in seizure paradigms. A number of selective 5-HT 3 receptor agonist and antagonists have been synthesized and pharmacologically characterized. None of these drugs has not been investigated in the seizure treatment. In this study, we determined effects of selective 5-HT 3 receptor agonist and antagonist on an experimental model of clonic seizure threshold induced by intravenous pentylenetetrazole (PTZ). 28 We also examined the possible involvement of the nitrergic system using the NOS substrate L-arginine and inhibitor N G -nitro-Larginine methyl ester (L-NAME) in the seizure propensity outcomes of these agents. This research could provide new insight into the role of the 5-HT 3 receptor and its relative pharmacological agents in modulating seizures, which could in turn divulge this branch in antiepileptic drug studies.
Materials and methods

Animals
Male adult Swiss mice weighting 24-30 g (Razi Institute) were used in this study. Animals were housed in standard conditions, including controlled temperature ($25 8C), 12 h dark/12 h light cycle, and with access to food and water ad labitum. Each mouse was used only once and each treatment group consisted of 6-8 animals. All experiments were conducted between 10:00 and 14:00. The study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by National Institutes of Health (NIH publication no. 85-23; revised 1985) and with the recommendations and approval of the Ethics Committee on Animal Experiments of the Tehran University/Medical Sciences. Each tested animal was immediately euthanized after seizure threshold determination.
Chemicals
Granisetron was used as 1 mg/ml injectable solution (manufactured and marketed by Roche, Switzerland) and was diluted, when needed, by saline solution. SR57227 (1-(6-chloro-2-pyridinyl)-4-piperidinamine) hydrochloride was purchased from Tocris (UK). Pentylenetetrazole (PTZ), L-NAME, and L-arginine were purchased from Sigma (UK). Drugs were all dissolved in sterile physiological saline. All injections were done in the volume of 10 ml/kg of the bodyweight of the mice. PTZ was prepared in physiological saline as 1% solution.
Seizure threshold determination
The threshold of PTZ-induced seizures was measured by an infusion of PTZ into the tail vein of freely moving mice at a constant rate of 0.6 ml/min via a 30-gauge needle, connected by a polyethylene tube to a Hamilton microsyringe. 29 Minimal dose of PTZ (mg/kg) required to induce general clonus was recorded. The general clonus was characterized by forelimb clonus followed by whole body clonus. As such, seizure threshold is dependent on PTZ dose administered and time-related.
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Experiments
First, animals received an intraperitoneal (i.p.) injection of different doses of SR57227 (5 or 10 mg/kg), or granisetron (3 or 10 mg/kg) 30 min prior to seizure threshold measurement. In the control group, mice received identical volumes of isotonic saline. Next, we investigated the effects of NO on interaction between serotonin and seizures. Sub-effective doses of SR57227 with L-NAME (60 mg/kg; 45 min prior to seizure, i.e. 15 min prior to SR57227), or sub-effective doses of granisetron with L-arginine (75 mg/kg; again 45 min prior to seizure) were co-administered, seeking for any probable additive effect.
Data analysis
Data are presented as mean AE standard error of the mean (S.E.M.). Student's t-test or One-way analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparisons were used, where appropriate, to analyze the data. The significance level was defined as p < 0.05.
Results
Effect of different doses of granisetron on seizure threshold
Granisetron (0 (saline), 3 or 10 mg/kg, i.p.) was injected 30 min prior to the seizure determination. One-way ANOVA followed by post hoc comparisons demonstrated that granisetron at 10 mg/kg could lower the threshold of PTZ-induced clonic seizure (P < 0.01; Fig. 1 ). However, a lower dose of granisetron (3 mg/kg, i.p.) failed to show this proconvulsant activity, and was thus selected as a subeffective dose.
Effect of different doses of SR57227 on seizure threshold
The 5-HT 3 receptor agonist SR57227 (0 (saline), 5 or 10 mg/kg, i.p.) was injected to groups of mice 30 min before the seizure experiment. Analysis using one-way ANOVA followed by post hoc comparisons showed the anticonvulsive effect of this agent at 10 mg/kg (P < 0.001), but not at 5 mg/kg (P > 0.05; Fig. 1) . Fig. 1 . Effects of granisetron and SR57227 on pentylenetetrazole (PTZ)-induced seizure threshold in mice. Drugs were administered intraperitoneally 30 min prior to seizure threshold determination. Data represent mean AE S.E.M. of 6-8 mice. **P < 0.01, and ***P < 0.001 compared to control group receiving normal saline (shown as dose 0).
Determination of the sub-effective doses of L-arginine and L-NAME
The NO precursor L-arginine and the NOS inhibitor L-NAME were used in subsequent steps and dose response studies for these agents were performed. L-Arginine (50, 75, and 100 mg/kg, i.p.) was administered 45 min prior to seizure threshold determination. As shown in Fig. 2 , a significant proconvulsive effect of L-arginine on PTZ-induced clonic seizures 33 was first demonstrated at 100 mg/ kg (P < 0.01). Therefore, a dose of 75 mg/kg was selected as a subeffective dose.
L-NAME (10, 20, 60 , and 100 mg/kg, i.p.) was administered 45 min prior to PTZ challenge. Post hoc comparison following oneway ANOVA revealed a highly significant anticonvulsive effect at 100 mg/kg (P < 0.01; not figured), but not at lower doses. L-NAME at 60 mg/kg (P < 0.05 compared to saline treated mice) was therefore selected as the minimally effective dose.
Co-administration of granisetron and L-arginine
Granisetron (3 mg/kg, i.p.) was co-administered with L-arginine (75 mg/kg, i.p.), each individually at a dose below that yielding a seizure modulating effect. As revealed by Student's t-test and demonstrated in Fig. 3 , the combination significantly decreased PTZ seizure threshold (P < 0.001).
Administration of SR57227 with L-NAME
Sub-effective dose of the 5-HT 3 receptor agonist SR57227 (i.e. 5 mg/kg, i.p.) was administered together with minimally effective dose of L-NAME (60 mg/kg, i.p.), and this combination yielded a very significant increase in seizure threshold (P < 0.001; Fig. 4 ).
Discussion
In the present study, we demonstrated that 5-HT 3 receptor agonists and antagonists alter the clonic seizure threshold induced by PTZ in mice, suggesting a role for 5-HT 3 receptors in brain excitability and expression of convulsive discharges. Using a selective 5-HT 3 receptor agonist and antagonist, we clearly found that higher 5-HT 3 receptor stimulation was accompanied with higher thresholds of PTZ-induced clonic seizures in mouse.
Selective antagonism of baseline 5-HT 3 activity by granisetron decreased the PTZ-induced clonic seizure threshold. In contrast, selective augmentation of 5-HT 3 activity increased seizure threshold, suggesting a possible therapeutic role of serotonin agonists against seizures. Furthermore, this study demonstrated for the first time that the NO system may modulate the action of 5-HT 3 receptors during brain excitability.
The role of serotonin as an important neurotransmitter in seizure development and epileptogenesis is increasingly addressed in the scientific literature. 11 Although soma of serotonergic neurons in the central nervous system are limited to a series of midline brainstem nuclei -the raphe formations, 10 neuronal projections spread throughout most of brain, and particularly high concentrations of this receptor are distributed the cortical and limbic areas. In appropriate groups, normal saline was injected as control. ***P < 0.001 compared to control group receiving no drug. Fig. 4 . Additive effect of SR57227 and L-NAME when co-administered in subeffective doses (5 and 60 mg/kg, i.p., respectively). Both drugs were administered intraperitoneally; L-NAME 45 min and SR57227 30 min prior to seizure threshold determination. In appropriate groups, normal saline was injected as control. ***P < 0.001 compared to control group receiving no drug.
and chemically induced paroxysms. [40] [41] [42] Concerning SSRIs, they have been shown to exert anticonvulsive properties in epileptic patients 17, 43 and different animal models of epilepsy, 14, 15, 17, 44 and they also have been demonstrated to enhance the effect of antiepileptic drugs in experimental settings. [45] [46] [47] Most of 5-HT receptors are metabotropic, and found to be genetically related; but 5-HT 3 is considered dissimilar to other classes particularly in being a ligand-gated ion channel. 3 Clinically, 5-HT 3 antagonists (ondansetron, granisetron, and tropisetron) are typically used as potent antiemetics, due to the important central and peripheral role of 5-HT 3 receptors in the nausea/emesis centers. Some case reports have described seizures in patients provoked by ondansetron. 48, 49 Previous experimental studies on the effects of 5-HT 3 receptor agonists and antagonists on seizure propensity, however, have been limited. Watanabe et al. 50 have studied electrically induced focal hippocampal seizures in rats and found no effect of the 5-HT 3 receptor agonist SR57227 (up to 3 mg/kg; i.p.), 50 and only a decrease in the primary after-discharge duration and the latency of secondary after-discharge measures following granisetron administration. 51 Wada et al. have suggested a facilitator role for 5-HT 3 in development of amygdala-kindled rats using intra-cerebroventricular injection of a 5-HT 3 agonist. 52 Balakrishnan and colleagues even reported an anticonvulsant profile for ondansetron in maximal electroshock-induced seizures in rats. 53 Contrarily, this 5-HT 3 antagonist was also shown to increase hippocampal theta rhythm 5 and to decrease the firing rate of hippocampal inhibitory interneurons, 54 leading to an increase firing rate of pyramidal cells.
Cortical and hippocampal interneurons expressing this 5-HT 3 receptor are mainly inhibitory in nature, acting on excitatory neurons.
2,55-57 Thus, stimulation of these interneurons increase the seizure threshold. Ropert and Guy had shown that hippocampal GABAergic interneurons are directly excited via 5-HT 3 transmission. 58 A postulated mechanism for this anticonvulsive effect of 5-HT 3 agonism may be activation of the 5-HT 3 receptor as an inward Na + , Ca
2+
, outward K + conducting ion channel, resulting in early depolarization of inhibitory interneurons. 1, 4 This may explain the anticonvulsive properties reported for SSRIs (which generally augment synaptic serotonin) as well our data presented here. Similarly, blocking the baseline endogenous stimulation of 5-HT 3 receptors by granisetron induces proconvulsive properties. GABAergic interneurons also express presynaptic 5-HT 3 receptors on their axonal terminals, 59, 60 and the 5-HT 3 agonist mchlorophenylbiguanide (mCPBG) has been shown to facilitate GABA release in a synaptic bouton preparation of hippocampal CA1 pyramidal neurons. 60 It is plausible that increased Ca 2+ conductance at the 5-HT3 channel/receptor could modulate a GABAergicmediated increase in seizure threshold. 61, 62 The additive actions of sub-effective granisetron and L-arginine together to produce a significant proconvulsive effect, along with the additive anticonvulsant actions of sub-effective SR57227 and L-NAME suggest that the NO system modulates 5-HT 3 receptors function during seizure expression.
Nitric oxide synthase (NOS) enzyme has been shown to have close connection with other Ca 2+ conducting neuronal channels, especially the glutamate NMDA receptor/channel, and to also take part in NMDA modulation of seizure paradigms. 63 In general, NOS is considered as an enzyme highly dependent to Ca 2+ and calcium binding proteins (especially calmodulin) in terms of activity 64 and even destruction. 65 Depending on the studied seizure model, NO has been suggested to be either an anticonvulsant [66] [67] [68] Briefly, 5-HT 3 activation may have two opposite effects on the inhibitory interneuron; one toward increased firing and subsequent GABA release, which is anticonvulsive, and another towards increased NOS activity and proconvulsive consequences. Hence, one could suggest a ''masked'' anticonvulsant effect from pure 5-HT 3 agonists, at least at lower doses. Concomitant presence of a NOS inhibitor agent, as we performed with the addition of L-NAME, could ''unmask'' and potentiate the anticonvulsive pathway (Fig. 5) . This effect might also take part in other downstream neuronal circuits where NO may again oppose decreased seizure propensity.
One limitation for immediate progression to clinical application is the potential central and peripheral side effects of 5-HT 3 agonists. Using low doses of these agents with NOS inhibitors, or development of mixed 5-HT 3 agonist/NOS inhibitor agents could be solutions to benefit their anticonvulsant properties. In addition, thanks to human genome research, 5-HT 3 receptor subtypes are widely researched. Identifying the potential differences in human expression of 5-HT 3 which could guide pharmaceutical research towards development of more specific antiepileptic drugs.
In conclusion, this study demonstrates an anticonvulsant role for a selective 5-HT 3 receptor agonist. Furthermore, it demonstrates that NO system is involved in the effects of 5-HT 3 receptor signaling on seizure propensity. Fig. 5 . Proposed mechanism for the interaction of 5-HT 3 and NO system in modulation of seizure threshold in GABAergic interneurons. 5-HT3 R, 5-HT 3 receptor; NMDA R, NMDA receptor; nNOS, neuronal NO synthase; ", increase.
